Literature DB >> 10796480

Combined inhaled anticholinergic agents and beta-2-agonists for initial treatment of acute asthma in children.

L H Plotnick1, F M Ducharme.   

Abstract

BACKGROUND: Anti-cholinergic agents and beta2-agonist drugs are both bronchodilators used to reverse acute bronchospasm in children with asthma. These drugs have different modes of action, so may have complementary or additive effects.
OBJECTIVES: The objective of this review was to assess the effects of adding inhaled anti-cholinergics to beta2-agonists in acute paediatric asthma. SEARCH STRATEGY: We searched Medline (1966 to 1996), Embase (1980 to 1995), Cinahl (1982 to 1995) and reference lists of studies. We also contacted drug manufacturers and researchers. SELECTION CRITERIA: Randomised trials comparing the combination of inhaled anti-cholinergics and beta2-agonists with beta2-agonists alone in children aged 18 months to 17 years with acute asthma. DATA COLLECTION AND ANALYSIS: Assessments of trial quality and data extraction were done by two reviewers independently. MAIN
RESULTS: Ten trials involving a total of 836 children were included. Most trials were of high quality. When only one dose of anti-cholinergic inhalation was added to beta2-agonist therapy, there was an improvement in forced expiratory volume in one second after 60 minutes with combination therapy (weighted mean difference 16.1%, 95% confidence interval 5.5 to 26. 7% reduction). There was no reduction in hospital admission (odds ratio 0.80, 95% confidence interval 0.35 to 1.82, using a random effects model). For multiple doses in children with severe asthma, there was a reduction in forced expiratory volume in 1 second (weighted mean difference 9.8% predicted, 95% confidence interval 6. 5 to 13.1% predicted). There may also be a reduction in hospital admission (odds ratio 0.62, 95% confidence interval 0.38 to 0.99). Eleven children would need to be given multiple doses of anti-cholinergics in combination with beta2-agonists to avoid one hospital admission compared to children given beta2-agonists alone. REVIEWER'S
CONCLUSIONS: In children with acute asthma, the addition of multiple doses of anti-cholinergics to inhaled beta2-agonists appears to improve lung function modestly and may decrease hospital admission. There is no associated increase in adverse effects. Single doses of anti-cholinergics may improve lung function in children with severe asthma, but do not appear to reduce hospital admissions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10796480     DOI: 10.1002/14651858.CD000060

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  4 in total

1.  Audit of acute asthma management at the Paediatric Emergency Department at Wad Madani Children's Hospital, Sudan.

Authors:  Salma M H Ibrahim; Huda M Haroun; Hassan M Ali; Imad Eldeen M Tag Eldeen
Journal:  Sudan J Paediatr       Date:  2012

2.  Effect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial.

Authors:  Suzanne Schuh; Judy Sweeney; Maggie Rumantir; Allan L Coates; Andrew R Willan; Derek Stephens; Eshetu G Atenafu; Yaron Finkelstein; Graham Thompson; Roger Zemek; Amy C Plint; Jocelyn Gravel; Francine M Ducharme; David W Johnson; Karen Black; Sarah Curtis; Darcy Beer; Terry P Klassen; Darcy Nicksy; Stephen B Freedman
Journal:  JAMA       Date:  2020-11-24       Impact factor: 56.272

Review 3.  Changing approaches to asthma management in Australia: effects on asthma morbidity.

Authors:  E Comino; R Henry
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Asthma across the ages: knowledge gaps in childhood asthma.

Authors:  Stanley J Szefler; James F Chmiel; Anne M Fitzpatrick; George Giacoia; Thomas P Green; Daniel J Jackson; Heber C Nielsen; Wanda Phipatanakul; Hengameh H Raissy
Journal:  J Allergy Clin Immunol       Date:  2013-11-28       Impact factor: 10.793

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.